Chimerix’s (CMRX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a research note released on Tuesday,RTT News reports. They currently have a $7.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $6.00.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a report on Tuesday.

Chimerix Stock Up 10.0 %

Shares of Chimerix stock opened at $4.82 on Tuesday. Chimerix has a twelve month low of $0.75 and a twelve month high of $5.15. The business has a 50-day moving average price of $3.64 and a 200 day moving average price of $1.88. The firm has a market cap of $433.42 million, a PE ratio of -5.13 and a beta of 0.35.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Stoneridge Investment Partners LLC boosted its holdings in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares during the last quarter. Bender Robert & Associates acquired a new position in shares of Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the 4th quarter worth approximately $62,000. Finally, Diadema Partners LP acquired a new position in shares of Chimerix during the 4th quarter worth approximately $101,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.